Introduction
Multiple myeloma is an incurable hematological malignancy that is resistant to several chemotherapeutic agents as well as hematopoietic stem cell transplantation (Attal et al., 2003) . Recently, several new types of agents for myeloma, such as thalidomide, lenalidomide and the proteasome inhibitor bortezomib, have been analysed, but these agents do not lead to long-term complete remission of myeloma, although they are very effective and improve the survival duration of patients (Singhal et al., 1999; Hideshima et al., 2001 Hideshima et al., , 2003 . In contrast, the new types of molecular target agents for leukemia and lymphoma include imatinib, which targets bcr-abl tyrosine kinase and brings about striking improvement of the remission and survival rates of chronic myeloid leukemia patients, and rituximab, which targets CD20 antigen on the surface of B lymphoma cells and improves the remission and survival rates of lymphoma patients. These observations indicate that understanding the pathogenesis of a disease is very important for designing new types of molecular target agents. Nevertheless, in contrast to leukemia and lymphoma, the pathogenesis of multiple myeloma is still not well understood.
The PU.1 is an ETS family transcription factor that is important for both myelopoiesis and lymphopoiesis (Klemsz et al., 1990; McKercher et al., 1996) . Gene expression generally requires long-range distal enhancer regions in addition to the promoter region (Yu et al., 1999; Loots et al., 2000; Radomska et al., 2002; Okuno et al., 2002a Okuno et al., , 2002b . In the case of the PU.1 gene, the long-range distal enhancer region is located in a 14-kb 5 0 -upstream region in mice and a 17-kb 5 0 -upstream region in humans (Li et al., 2001; Okuno et al., 2005; Tatetsu et al., 2007) . In Friend leukemia, FEEV is integrated into the 14-kb 5 0 -upstream region of the PU.1 gene locus and results in failure of PU.1 downregulation in erythroblasts, thereby leading to erythroleukemia in mice (Moreau-Gachelin et al., 1988) . We earlier reported that proper murine PU.1 gene expression requires the 14-kb 5 0 -upstream regulatory region, which consists of two highly conserved regions among different mammals, and that the FEEV integration site in Friend leukemia is located between these two conserved regions (Okuno et al., 2005) . Moreover, conditional knockout of this 14-kb 5 0 -upstream region led to downregulation of PU.1 to 20% of wild-type mice, and all of these mice developed acute myeloid leukemia (Rosenbauer et al., 2004) . These mice also developed T-cell lymphoma with upregulation of PU.1 in T lymphoma cells, because one of the two highly conserved regions in the 14-kb 5 0 -upstream region has suppressor activity for PU.1 expression in the T-cell lineage through wnt signaling (Rosenbauer et al., 2006) . These data indicate that inappropriate regulation of the PU.1 gene, including failure of downregulation or upregulation in proper differentiation stages, leads to hematological malignancies in different hematological lineages (Tenen, 2003) .
We recently reported that PU. 1 is downregulated in the majority of myeloma cell lines and freshly isolated myeloma cells from a subset of multiple myeloma patients (PU.1 low-to-negative subset), whereas normal plasma cells express relatively high levels of PU.1 (Tatetsu et al., 2007) . The PU.1 is downregulated by methylation of the 17-kb 5 0 -enhancer region and the promoter region in myeloma cell lines, whereas only the promoter region is methylated in T-cell lines (Amaravadi and Klemsz, 1999) . Myeloma patients in the PU.1 low-to-negative subset may have a poor prognosis. In addition, conditional expression of PU.1 in PU.1-negative myeloma cell lines, U266 and KMS12PE, was found to induce cell growth arrest and apoptosis (Tatetsu et al., 2007) . These data suggest that downregulation of PU.1 may be an important genetic change for oncogenesis or growth maintenance of multiple myeloma cells. To elucidate the effects of PU.1 expression in U266 cells, we performed DNA microarray analyses and compared the differences in gene expression before and after PU.1 expression.
Results
Interferon-stimulated genes are mainly upregulated in the U266 myeloma cell line after PU.1 induction As earlier reported (Tatetsu et al., 2007) , we generated a stable U266 tetPU.1 cell line derived from the PU.1-negative myeloma cell line U266 with a tet-off conditional expression system of PU.1. RNA was purified from U266 tetPU.1 cells before (day 0) and at days 1 and 3 after PU.1 induction and subjected to DNA microarray analyses (Illumina:Sentrix Human-6 Expression BeadChip). The expression levels of genes were analysed using the GeneSpring7.2 software, and compared among days 0, 1 and 3. A total of 47 296 human genes were analysed, among which 21 565 genes were found to be expressed and 25 731 genes were not expressed. Among the 21 565 genes expressed, 479 genes were upregulated by more than twofold and 1697 genes were downregulated by more than 50% on either day 1 or day 3 after PU.1 induction. The 30 genes showing the highest upregulation after PU.1 induction are shown in Table 1 (day 1) and Supplementary Table S1 (day 3).  IFIT1, IFITM1, IFIT2, IFIT4, IFI27, G1P2 , C1orf29, LY6E, LAMP3 and G1P3, which are known as IFNstimulated genes (de Veer et al., 1998) , were upregulated by more than 20-fold at day 1 and more than fivefold at day 3. These upregulations were confirmed by semiquantitative PCR of IFIT4 and IFI27 (data not shown). These data indicate that PU.1 induction activated the expression of many IFN-stimulated genes in U266 myeloma cells. In contrast, the 30 most downregulated genes at day 1 and day 3 after PU.1 induction are shown in Supplementary Table S2 and Supplementary Table  S3 . Among these downregulated genes, Syndecan 1, which is a marker of plasma cells and known as CD138, was the most downregulated gene 3 days after PU.1 induction.
Cell cycle arrest induced by PU.1 may be partially related to upregulation of p21 Next, we analysed the mechanisms of the cell growth arrest of U266 cells induced by PU.1 by comparing the gene expression profiles of cell cycle-related genes. Most of the cyclin genes, particularly cyclin A2, B1, B2, D1, D2 and E2, were all continuously downregulated from day 1 to day 3 after PU.1 induction, and E2F1 and E2F2 were also downregulated (Table 2) . Regarding the CDK families, CDK2 and CDK4 were downregulated to 77 and 40%, respectively. We earlier confirmed downregulation of cyclin D1 at the protein level (Tatetsu et al., 2007) . In addition, cyclins, CDKs, and E2F were analysed by western blot. We confirmed that cyclin A2 and B1, CDK2 and CDK4 were also downregulated at the protein levels (Figure 1) , whereas E2F2 protein level was not changed (data not shown). The downregulation of these cyclins and CDK family members was consistent with the growth arrest of U266 tetPU.1 cells after PU.1 induction. We further evaluated the expression profiles of growth inhibitory genes, such as the tumor suppressor genes p53, p15 and p16, and found that only p21 was upregulated by 3.4- fold at day 1 and 2.2-fold at day 3 after PU.1 induction ( Table 2 ). The protein level of p21 was also increased by 4.3-fold ( Figure 1 ). Therefore, we next evaluated the effect of upregulated p21 on the growth arrest of U266 tetPU.1 cells expressing PU.1 by knocking p21 using stably expressed small interference RNAs (siRNAs) (Figure 2a ). Suppression of p21 partially restored growth of U266 tetPU.1 cells expressing PU.1, suggesting that p21 may be partially involved in the growth arrest of U266 tetPU.1 cells induced by PU.1 (Figure 2b ).
IRF7 shows the highest upregulation and IRF4 does strong downregulation among transcription factors after PU.1 induction Among the genes upregulated after PU.1 induction, IRF7 was the only transcription factor that was highly upregulated at both day 1 (24.8-fold) and day 3 (6.0-fold) after PU.1 induction (Table 1 and Supplementary  Table S1 ). The protein level of IRF7 was also highly upregulated, as evaluated by western blotting analysis ( Figure 1 ). Therefore, we speculated that IRF7 may be a key molecule for activating the expression of IFN-stimulated genes. In contrast, IRF4, which is also known as MUM1 or Pip and is highly expressed in almost all myeloma cells (Iida et al., 1997) , was downregulated to 44% at day 1 and 36% at day 3. Protein level of IRF4 was also strongly downregulated to 1.8% at day 2 and 18% at day 3 after PU.1 induction (Figure 1 ). Other upregulated transcription factor in both mRNA and protein levels was STAT1, which binds to IRFs and translocates to the nucleus during interferon signal transduction. In conclusion, both the most upregulated transcription factor, IRF7, and the strongly downregulated transcription factor, IRF4, belong to the interferon signal transduction pathway.
We next evaluated the expression levels of genes involved in lineage commitment and differentiation. The critical transcription factors for lineage commitments were evaluated with the DNA microarray data, and RUNX1, which is essential for definitive hematopoiesis and directly regulates PU.1 (Huang et al., 2008) , was found to be downregulated to about 50% at days 1 and 3 after PU.1 induction, although no changes in expression were detected for GATA-2 and C/EBPa. To confirm protein expression levels of these transcription factors, we performed western blot analyses and found that protein levels of RUNX1 and C/EBPa were downregulated to 44 and 57% 3 day after PU.1 induction, respectively ( Figure 1 ). In contrast, protein level of GATA-2 was not changed and there was no expression of GATA-1 in U266 tetPU.1 cells both before and after PU.1 induction by western blot analyses.
TRAIL may be a key molecule for apoptosis of U266 tetPU.1 and KMS12PE
tetPU.1 cells induced by PU.1 Among the apoptosis-related genes, TRAIL (TNFSF10), a ligand for death receptors DR4 and DR5, was upregulated by 76.5-fold at day 1 (Table 1 ) and 1.7-fold at day 3 after PU.1 induction in U266 tetPU.1 cells, and these data were confirmed by real time-PCR (44.0-fold at day 2) (Figure 3a ). Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) was also strongly upregulated (12.1-fold at day 2) after PU.1 induction in KMS12PE tetPU.1 cells ( Figure 3a) . It is well known that TRAIL can induce apoptosis in myeloma cells (Mariani et al., 1997; Mitsiades et al., 2002) . Therefore, to clarify whether TRAIL is a key molecule for the apoptosis of U266 tetPU.1 and KMS12PE tetPU.1 cells induced by PU.1, we stably introduced siRNAs for TRAIL into both cell lines and obtained stable transformants showing strong knockdown of TRAIL ( Figure 3a ). Stable expression of siRNA targeting TRAIL inhibited apoptosis of U266 tetPU.1 and KMS12PE
tetPU.1 cells induced by PU.1, whereas scrambled siRNAs did not (Figure 3b ), and the difference in apoptosis between siRNA for TRAIL and its scrambled counterparts was statistically significant ( Figure 3c ). Taken together, TRAIL may mainly induce apoptosis in U266 tetPU.1 and KMS12PE tetPU.1 cells after PU.1 expression.
PU.1 directly binds to the TRAIL promoter in U266
tetPU.1 and KMS12PE
tetPU.1 cells Next, we examined how TRAIL was induced after PU.1 expression. It was earlier reported that IRF3 upregulated the TRAIL promoter after paramyxovirus infection (Kirshner et al., 2005) . In our microarray data, IRF3 was not upregulated, whereas IRF7 was highly upregulated, after PU.1 induction in U266 tetPU.1 cells. Therefore, we performed chromatin immunoprecipitation assays of the TRAIL promoter with anti-IRF7 and anti-PU.1 antibodies, and unexpectedly found that PU.1 itself, but not IRF7, directly bound to the TRAIL promoter ( Figure 4a ). In case of KMS12PE tetPU.1 cells Figure 4b ). Therefore, we evaluated the TRAIL promoter to search for transcription-binding sites and found one potential PU.1-binding site located in 30-bp 3 0 -downstream of the transcription start site (Figure 5a ). We performed electromobility shift assays using oligonucleotides harboring the potential PU.1-binding site and nuclear extracts of U266 tetPU.1 cells and identified several bands for protein binding (Figure 5b ). Competition with CD11b promoter oligonucleotides including the PU.1-binding site and addition of the anti-PU.1 antibody eliminated one band for protein binding (Figure 5b , lanes 4 and 5) of the oligonucleotides for the 30-bp 3 0 -downstream region of the transcription start site (Figure 5a ), indicating that the binding to the oligonucleotides was PU.1 specific. We also identified the same PU.1-binding complex with the same oligonucleotides and nuclear extracts of KMS12PE tetPU.1 cells expressing PU.1 (Figure 5c ). In addition, in vitrotranslated PU.1 protein bound to the same oligonucleotides and CD11b oligonucleotides and the anti-PU.1 antibody eliminated the binding (Figure 5d , lanes 1-5), indicating that PU.1 binds to the oligonucleotides. Next we introduced mutations into the PU.1-binding site (GAGA to TCGC) in the oligonucleotides and performed electromobility shift assays. We detected two major shifted bands, but these did not disappear after competition with the CD11b oligonucleotides or addition of the anti-PU.1 antibody (Figure 5d , lanes 6-10), indicating that the mutations in the PU.1-binding motif completely abolished PU.1 binding to the TRAIL promoter region. Therefore, these data indicate that PU.1 binds to the 30-bp 3 0 -downstream region of the transcription start site of the TRAIL promoter. Days 3 Figure 1 The IRF7 and p21 WAF1/CIP were upregulated and IRF4 was downregulated in U266 tetPU.1 cells after PU.1 induction. Western blotting analyses of cell cycle-related genes, IRFs, STATs and transcription factor essential for hematopoiesis were performed on cell extracts of U266 tetPU.1 cells before (lane 1) and at day 2 (lane 2) and day 3 (lane 3) after PU.1 induction by removal of tetracycline. Right panels are based on the densitometry of the left panel. Each expression level of day 0 is set as 1, and relative expression levels at day 2 and 3 were shown in each right panel. (Figure 6a ). With the wild-type TRAIL promoter, the expression level was upregulated by 70-fold in U266
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tetPU.1 cells and 26-fold in KMS12PE tetPU.1 cells compared with that of pGL4.26 alone when tetracycline was not removed (without PU.1 expression) (Figures 6b  and c) . In addition, when PU.1 was upregulated, reporter gene expression was highly upregulated by 4.6-fold compared with that with no PU.1 expression in U266 tetPU.1 cells, and 6.6-fold in KMS12PE tetPU.1 cells. We further examined whether the upregulated reporter gene expression was dependent on PU.1 binding to the TRAIL promoter. To achieve this, we introduced the same mutations (GAGA to TCGC) into the PU.1-binding site in the 30-bp 3 0 -downstream region of the transcription start site of the TRAIL promoter construct that were shown to abolish PU.1 binding in electromobility shift assays (Figure 5d ), and found that these mutations completely eliminated the upregulation of reporter gene expression relative to the control plasmid (pGL4.26) in both U266 tetPU.1 and KMS12PE
tetPU.1 cells regardless of whether or not PU.1 was induced (Figures 6b and c) . Taken together, these data suggest that TRAIL expression in both U266
tetPU.1 and KMS12PE tetPU.1 cells expressing PU.1 is highly dependent on direct binding of PU.1 to the TRAIL promoter.
Discussion
We earlier reported that downregulation of PU.1 in myeloma cells is necessary for their growth and survival, and that conditional expression of PU.1 in myeloma cells induced growth arrest and apoptosis (Tatetsu et al., 2007) . In this study, we analysed the genes involved in the growth arrest and apoptosis of U266 myeloma cells by performing DNA microarray analyses and comparing the gene expressions before and after PU.1 induction. We found that among cell cycle-related genes, p21 was upregulated and cyclin A2, cyclin B1, CDK2 and CDK4 were downregulated after PU.1 induction. Among apoptosis-related genes, TRAIL was directly transactivated by PU.1 and induced apoptosis in both U266 tetPU.1 and KMS12PE tetPU.1 cells expressing PU.1. After PU.1 induction, many cyclins and CDKs were downregulated, and these findings are compatible with the growth arrest of U266 cells. In contrast, among tumor suppressor genes, only p21 was upregulated after PU.1 induction, and this was confirmed at the protein level. Given the fact that knockdown of p21 by siRNA partially rescue the PU.1-induced growth arrest of U266 tetPU.1 cells, p21 may partially mediate the induction of growth arrest of myeloma cells by PU.1. The mechanism of the upregulation of p21 after PU.1 induction in U266 tetPU.1 cells is now being elucidated. It was reported that IRF1 directly transactivates p21 gene expression by binding to the p21 gene promoter (Coccia et al., 1999) . Among the IRF family members, IRF7 and IRF9 were highly upregulated at 24.8-fold and 3.9-fold in mRNA levels, respectively. It is reasonable that these IRFs may induce p21 expression after PU.1 induction.
We also evaluated the gene expression levels of apoptosis-related genes in U266 cells expressing PU.1 and found that TRAIL was highly upregulated after PU.1 induction and stably expressed siRNAs for TRAIL suppressed the apoptosis of not only U266 
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S Ueno et al PU.1 expression, because it was found to effectively induce apoptosis in multiple myeloma cells in vitro (Mariani et al., 1997; Gazitt, 1999; Mitsiades et al., 2001 Mitsiades et al., , 2002 . We further found that PU.1 itself directly transactivates the TRAIL promoter in both myeloma cell lines. This is a first report to show that PU.1 is a direct transactivator of TRAIL gene expression. From this aspect, PU.1 may be a regulator of unlimited proliferation of hematopoietic cells including plasma cells through upregulation of the cell death inducer TRAIL.
As shown in Figures 3b and c , siRNA for TRAIL may not completely suppress apoptosis of U266 tetPU.1 and KMS12PE
tetPU.1 cells after PU.1 expression, suggesting that other factors may be involved in the apoptosis of these cells. IRF4 is an essential transcription factor for generation of plasma cells, because transgenic mice with a conditional knockout of Irf4 in germinal center B cells were unable to differentiate memory B cells into plasma cells (Klein et al., 2006) . In addition, it was reported that knockdown of IRF4-induced apoptosis in many genetic types of myeloma cells (Shaffer et al., 2008) . Therefore, because protein levels of IRF4 were strongly downregulated to 0.02-fold at 2 days and 0.18-fold 3 days after PU.1 induction (Figure 1) , it is possible that this downregulation of IRF4 may also induce apoptosis in myeloma cells after PU.1 expression.
In this study, we found that PU.1 can directly transactivate TRAIL gene expression in myeloma cells. This finding may be universal for all hematopoietic cells, although we still need to analyse whether PU.1 also induces TRAIL gene expression in other hematopoietic Figure 3b , percentage of increases of apoptotic cells in U266 tetPU.1 and KMS12PE tetPU.1 cells stably expressing siRNA for TRAIL or its scrambles after PU.1 induction are shown compared with those before PU.1 induction (set as 100%). Means ± s.d. for three independent clones expressing siRNA for TRAIL or its scrambled siRNA are shown.
If this proves to be the case, upregulation of PU.1 may be a universal therapeutic molecular target for hematopoietic malignancies. Indeed, upregulation of TRAIL may represent a major target for HDAC inhibitors (Insinga et al., 2005; Nebbioso et al., 2005) , and this could be mediated by upregulation of PU.1. The PU.1 also induced downregulation of IRF4 that may result in apoptosis of myeloma cells (Shaffer et al., 2008) . Therefore, upregulation of PU.1 may represent a possible treatment of multiple myeloma by inducing the combination of upregulation of TRAIL and downregulation of IRF4.
Materials and methods

DNA microarray analysis
We earlier generated U266 tetPU.1 and KMS12PE tetPU.1 cells that express PU.1 by tet-off system (Tatetsu et al., 2007) . At first, RNA was extracted from U266 tetPU.1 cells at three different time points, before, and 1 or 3 days after tetracycline removal. To compare gene expression differences between before and after tetracycline removal, the microarray analysis was performed using Illumina:Sentrix Human-6 Expression BeadChip as recommended by the manufacturer. Expression levels of genes were analysed by GeneSpring 7.2 software.
Cell culture Human myeloma cell line U266 tetPU.1 and KMS12PE tetPU.1 cells, and their derivatives were grown in RPMI 1640 containing 10% fetal bovine serum at 37 1C.
Western blot analysis
The cell lysates were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes. The membranes were incubated with anti-PU.1, anti-p21
, anti-cyclin A2, anti-cyclin B2, anti-CDK2, anti-CDK4, anti-IRF1, anti-IRF4, anti-IRF7, anti-STAT1, anti-STAT2, anti-RUNX1, anti-C/EBPa, anti-GATA1, anti-GATA2, anti-Actin primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-cyclin B1 (Abcam, Cambridge, MA, USA) for 3-16 h. Finally, the membranes were incubated with peroxidase-labeled secondary antibodies for 1 h, and developed using an enhanced chemiluminescence system (Amersham Life Science Inc., Arlington Heights, IL, USA).
Generation of U266
tetPU.1 and KMS12PE tetPU.1 cells stably expressing siRNA for TRAIL or p21 and those scrambled siRNAs The siRNA expression vectors were generated by insertion of annealed oligonucleotides for TRAIL or p21 and those scrambled siRNAs into from BamHI to HindIII site of pRNA-U6.1/Zeo or pRNA-U6.1/Hygro (GenScript, Piscataway, NJ, USA) (Supplementary Information). These siRNA expression vectors were transfected to U266 tetPU.1 or KMS12PE tetPU.1 cells by elecrotoporation and stable transformants were obtained by zeocin or hygromycin selection.
Real-time PCR
Quantitative Taqman PCR was performed using commercially available assay on demand probe primer sets for TRAIL and b-actin (Applied Biosystems, Foster City, CA, USA) and Taqman Universal PCR Master Mix reagent using an ABI Prism 7700 Sequence Detection System (Applied Biosystems). The expression levels of b-actin were used to standardize the relative expression levels of TRAIL. The expression level of TRAIL in U266 tetPU.1 and KMS12PE tetPU.1 cells before tetracycline removal was set as 100.
Detection of apoptosis
To detect apoptosis of myeloma cells, the cells were stained with an Annexin V Phycoerythrin Apoptosis Detection kit (Medical and Biological Laboratories, Nagoya, Japan) and analysed for Annexin V expression with FACS caliber (Becton Dickinson, San Jose, CA, USA).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as described earlier (Okuno et al., 2005) . Briefly, 1 Â 10 7 of U266 tetPU.1 or KMS12PE tetPU.1 cells 1 day after tetracycline removal were treated with 0.5% formaldehyde and genomic DNA was extracted and sonicated. Small amount of genomic DNA was saved as input DNA. The total input sample was diluted 1/100 before being used as a template for PCR. Soluble chromatin was treated with anti-PU.1 antibody, anti-IRF7 antibody and rabbit IgG, and immunoprecipitated by protein A agarose beads (Santa Cruz Biotechnology). Each precipitated DNA was eluted and extracted as described earlier and subjected for PCR. PCR was performed using TRAIL promoter sense primers, 5 0 -TGAGGATATGTTAGG GAAAAGCA-3 0 located 284-bp upstream of transcription start site, and TRAIL exon 1 antisense primer 5 0 -GATCAC GATCAGCACGCAGGTCT-3 0 located 140-bp downstream of transcription start site. Oligonucleotides, 5 0 -ACTATAAAAGAATAGAGAAGGAA GGGCTTC-3 0 and 5 0 -GAAGCCCTTCCTTCTCTATTCTT TTATAGT-3 0 , were annealed and subjected to electromobility shift assay for PU.1-binding site in a 30-bp 3 0 -downstream region of the transcription start site of the TRAIL gene, whereas oligonucleotides, 5 0 -ACTATAAAAGAATATCGC AGGAAGGGCTTC-3 0 and 5 0 -GAAGCCCTTCCTGCGAT ATTCTTTTATAGT-3 0 were annealed and used as mutant oligonucleotides for the PU.1-binding site of the TRAIL promoter. Annealed oligonucleotides were labeled with [g-P 32 ]ATP using T4 polynucleotide kinase and incubated with nuclear extracts or in vitro-translated PU.1 protein in 10 mM HEPES (pH 7.8), 50 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, and 5% glycerol for 15 min at 0 1C. Reaction mixtures were separated with 6% polyacrylamide gels in 0.5 Â TBE buffer at 4 1C. Gels were dried before autoradiography. Anti-PU.1, anti-IRF4 and anti-IRF7 antibodies (Santa Cruz) were used for supershift assays. The CD11b promoter oligonucleotides harboring PU.1-binding site 5 0 -CTACTTCTCCTTTTCTGCCCTTCTTTG-3 0 and 5 0 -CAAA GAAGGGCAGAAAAGGAGAAGTAG-3 0 , which have been described earlier (Pahl et al., 1993) , were annealed and used for competition assays. 0 -non-coding region of exon 1. The sequence for oligonucleotides used for electromobility shift assay (EMSA) in Figures 5b-d is underlined (wild-type). A earlier described binding site for IRF3 is also shown (Kirshner et al., 2005) . (b, c) PU.1 binds to the 30-bp 3 0 -downstream region of the transcription start site. An EMSA was performed using nuclear extracts of U266 tetPU.1 (b) and KMS12PE tetPU.1 cells (c) at day 1 after PU.1 induction and the oligonucleotides shown in Figure 4a (wild-type). 'Self' refers to competition with itself. 'CD11b' refers to competition with oligonucleotides complementary to the CD11b promoter region including the PU.1-binding site (CD11b oligonucleotides). The relative position of the PU.1 complex is shown on the left side of the panels (arrow). The PU.1, IRF7 and IRF4 refer to antibodies used for supershift assays. The anti-PU.1 antibody does not create a supershift but instead eliminates the PU.1 complex (lane 5). In vitro-translated PU.1 generated PU.1-specific band as a positive control as shown in (d) (b, lanes 8-11) . (d) In vitro-translated PU.1 protein specifically binds to the 30-bp 3 0 -downstream region of the transcription start site. EMSAs were performed using in vitro-translated PU.1 and wild-type oligonucleotides or mutant oligonucleotides of the PU.1-binding site (GAGA to TCGC). The relative position of the PU.1 complex is shown on the left side of the panels (arrow). The CD11b oligonucleotides and anti-PU.1 antibody eliminate the PU.1 complex (lanes 4 and 5). In contrast to the PU.1 complex with the wild-type oligonucleotides, there is no PU.1 complex with the mutant oligonucleotides that can be diminished by competition with the CD11b oligonucleotides or anti-PU.1 antibody (lanes 7-10). Three independent pools for each plasmid transfection with or without tetracycline were prepared for reporter assays and the mean and the standard deviation for each pool are shown.
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